Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer

Status unconfirmed · Phase 2

Conditions studied: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with liver or bile duct cancer.

Key facts

Study ID

NCT00003296

Run by

Brown University

People needed

26

Starts

1998-01-01

Last updated by the study team

2013-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• New England Medical Center Hospital — Boston, Massachusetts, United States
• Brown University Oncology Group — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.